The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org). e purpose of this guideline is to provide information to allow the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of uoropyrimidines (5-uorouracil, capecitabine, and tegafur). Detailed guidelines for use of uoropyrimidines, their clinical pharmacology (see ref. 1 for review), and analyses of the cost-e ectiveness are beyond the scope of this article. e Clinical Pharmacogenetics Implementation Consortium guidelines consider the situation of patients for whom genotype data are already available. 2
GENE: DPYD Background
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for uoropyrimidine catabolism and eliminates >80% of administered 5-uorouracil. 3 DPD levels show high interand intraindividual variation, and this variability is likely to in uence response of patients to 5-uorouracil with respect to toxicity, resistance, and e cacy. 4 In patients who are de cient in DPD, 5-uorouracil can cause profound toxicity, such as myelosuppression, mucositis, neurotoxicity, hand-foot syndrome, and diarrhea. Familial studies have demonstrated that this is an autosomal codominantly inherited trait. 5 DPYD, the gene encoding DPD, is a large gene with 4,399 nucleotides in 23 coding exons spanning 950 kb on chromosome 1p22. 6 e most well-studied variant is DPYD*2A (also known as DPYD:IVS14 + 1G>A, c.1905+1G>A, or rs3918290). 7 It is a single-nucleotide polymorphism at the intron boundary of exon 14 that results in a splicing defect, skipping of the entire exon, and a nonfunctional protein. 8 Recently, O er et al. measured the relative sensitivity to 5-uorouracil of cells expressing DPD variations and con rmed that DPYD*2A is catalytically inactive. 9 is allele is considered relatively rare, although it is more common than most other known inactivating variants in DPYD. Estimates of the frequency of the *2A allele range from <0.005 (in the HapMap CEU, YRI, JPT, and HCB populations and several other studies) to 3.5% in a Swedish population. 10 e most frequently observed variants are *5 (rs1801159 T>C), *6 (rs1801160 C>T), and *9A (rs1801265 A>G) at frequencies of 11.5-30, 0.7-9, and 2.9-13.7%, respectively, and data regarding their e ects on DPD activity are contradictory. 6, [11] [12] [13] [14] However, the Dutch Pharmacogenetics Working Group has designated these alleles as "functional" on the basis of the lack of an association with toxicity reported in studies and/or decreased clearance or activity. 15 DPYD*3 (rs72549303 C>del), *13 (rs55886062 A>C), and rs67376798T>A are also relatively rare but result in low DPD activity and/or 5-uorouracil toxicity (see Supplementary Tables S1 and S2 online) . 5, 16, 17 Moreover, most variants of phenotypic consequence in DPYD are of very low frequency, and several studies did not observe any individuals with these variants. 11, 13, 14, 18, 19 Recently, a novel DPYD variant (Y186C) was identi ed only in the African-American population (found in 26% of African-American patients with reduced DPD activity). Individuals carrying this allele had a 46% reduction in DPD activity as compared with noncarriers. 20 Patients with <70% of the mean observed leukocyte DPD protein activity in the normal population are considered at risk for the development of severe toxicity a er administration of 5-uorouracil (or its prodrugs). 21 e relationship between DPYD genotype and phenotype is complicated; although several variants have been associated with low DPD activity (*2A, *13, and rs67376798) and uoropyrimidine toxicity (*2A, *13, and rs67376798) or have been observed in other cases of toxicity (*2A, *4, *6, *9A, *13, and rs67376798), the presence of these variants does not always result in toxicity, and associations have not been consistently replicated (discussed in refs. 9, 11, 19, 22 and other publications).
e inconsistency in study results may be explained by the substantial variation in treatment regimens across studies. In a study by Schwab et al. 11 including 683 cancer patients, DPYD*2A was found to play a limited role in 5-uorouracilrelated toxicity; of note, only patients receiving 5-uorouracil monotherapy were included. By contrast, Morel et al. found strong associations in a cohort of 487 patients between both DPYD*2A and rs67376798 and severe 5-uorouracil toxicity in patients receiving combination therapy. Studies linking DPYD*2A to toxicity generally include patients on combination therapies, suggesting that concomitant drugs may enhance the e ect of DPYD risk alleles. Furthermore, Schwab et al. also observed a higher rate of severe toxicities in patients receiving bolus-based 5-uorouracil than in patients receiving continuous infusion, suggesting a dose-dependent e ect of 5-uorouracil. Moreover, several studies have shown that only ~50% of heterozygote carriers of a low-activity allele develop severe 5-uorouracil toxicity. 11, 18, 19 is may indicate allelic regulation of DPYD or compensation by another DPYD variant on the second allele, resulting in greater DPD activity. 22 Recently, DPYD haplotypes (e.g., haplotype B3) have been considered to be more predictive in identifying patients at risk for severe 5-uorouracil-related 19 and capecitabine-related toxicities (grade ≥3). 23 However, data on functional consequences of these haplotypes are so far incomplete. Promoter methylation altered expression in cell lines; 24 however, methylation was not associated with toxicity in patients. 11 MicroRNAs have also been implicated in the regulation of DPYD, but their relevance for the modulation of DPD phenotypes with respect to drug response has not been tested. 25 Nevertheless, >20% (23.3-38%) of 5-uorouracil toxicities can be explained by combining multiple DPYD variants, suggesting a signi cant importance of DPYD variation for the risk of 5-uorouracil-related toxicities. 18, 19, 26, 27 
Genetic test interpretation
Each named * allele is de ned by the genotype at one or more speci c single-nucleotide polymorphisms ( Supplementary  Table S1 online). DPD function associated with the most common allelic variants is summarized in Supplementary Table S2 online. Table 1 summarizes the assignment of the probable DPD phenotype on the basis of the * allele diplotypes, and these assignments are used to link genotypes with uoropyrimidine dosing. Brie y, homozygotes of *2A, *13, and rs67376798 are considered de cient in DPD; heterozygotes for any combination of *2A, *13, and rs67376798 have intermediate or partial DPD activity; and those with none of these alleles are likely to have normal, high activity. DPYD alleles have been extensively studied in multiple geographically, racially, and ethnically diverse groups and are summarized in Supplementary Tables  S3 and S4 online. Because of con icting data or weak evidence for alleles other than *2A, *13, and rs67376798, this guideline does not currently report dosing recommendations for other variants of DPYD. Reports of other variants and phenotypes are discussed in the Supplementary Material online.
Available genetic test options
ere are several testing options for DPYD genotype, although, at present most test only for the DPYD*2A variant. A list of testing services is provided in an online linked format at PharmGKB (http://www.pharmgkb.org/gene/PA145) and the National Institutes of Health Genetic Testing Registry (http://www.ncbi. nlm.nih.gov/gtr/conditions/C2720286/ or http://www.ncbi.nlm. nih.gov/gtr/conditions/CN077983/).
Incidental findings
Individuals who harbor one copy of variant DPYD can be considered to have carrier status for an inborn error of metabolism, and consideration should be given to its potential e ects on o spring. Patients homozygous for inactivating variants of the DPYD gene have DPD de ciency, a disease that shows large phenotypic variability, ranging from no symptoms to severe convulsive disorders with motor and mental retardation. 28, 29 Other considerations
Several other genes may in uence responses to 5-uorouracil 3, 11 (see Supplementary Material online). e well-studied genes among these are ABCB1, MTHFR, and TYMS, although results have been inconsistent to date, and predictive dosing strategies have yet to be successfully applied. Some of the testing options for 5-uorouracil toxicity and DPYD also include testing for other gene variants in TYMS and MTHFR. For a summary of pharmacogenomic studies of 5-uorouracil, see the PGx Research tab at http://www.pharmgkb.org/drug/ PA128406956. ere are alternatives to genotyping of DPYD that assess DPD activity directly, including dihydrouracil/uracil ratio determination in plasma, the uracil breath test method, measurement of DPD activity in peripheral mononuclear cells, and pharmacokinetically guided strategies such as the 5-uorouracil test dose method (see ref. 30 for further information). Studies using dose reduction of 5-uorouracil in patients with DPD de ciency, as evidenced by the use of one of these functional tests, have shown a reduction in drug-related toxicities while maintaining e cacy in these patients. 31, 32 
DRUGS: FLUOROPYRIMIDINES Background
Fluoropyrimidines such as 5-uorouracil, capecitabine, and tegafur are widely used in the treatment of solid tumors, including colorectal and breast cancer and cancers of the aerodigestive tract. More than 2 million patients receive these types of drugs annually. 19 Approximately 10-40% of 5-uorouracil patients develop severe, and sometimes life-threatening, toxicity (neutropenia, nausea, vomiting, severe diarrhea, stomatitis, mucositis, hand-foot syndrome, and neuropathy). 19 Only 1-3% of the administered 5-fluorouracil dose has been found to be metabolized to cytotoxic metabolites, with ~80% of the administered dose being degraded or excreted in the urine. DPD is the first and rate-limiting step in the catabolic pathway converting 5-uorouracil to dihydro uorouracil. 3 Dihydro uorouracil is then converted to uoroβ-ureidopropionate and fluoro-β-alanine, which are then excreted in the urine (http://www.pharmgkb.org/pathway/ PA150653776). 3 Capecitabine and tegafur are prodrugs of 5-uorouracil that are converted to 5-uorouracil and then metabolized by DPD as described above.
Fluoropyrimidines are mostly used in combination with various other antineoplastic drugs. Disease and treatment regimens (which are also related to disease background-for example, breast cancer patients tend to receive bolus 5-uorouracil, whereas colorectal cancer patients tend to receive infusion 5-uorouracil) may also in uence the importance of DPD activity to risk for toxicity.
Linking genetic variability to variability in drug-related phenotypes
ere is substantial evidence linking DPYD genotype with phenotypic variability in DPD enzyme activity, 5-uorouracil clearance, and subsequently 5-uorouracil toxicity ( Supplementary  Table S5 online). Evidence providing the basis for the dosing recommendations ( Table 2) is from two large prospective studies, 11, 18 small studies with retrospective genotyping of patients with severe toxicity, and case studies (see Supplementary  Table S5 online).
5-Fluorouracil has a relatively narrow therapeutic window, resulting in a small di erence between an e cacious dose and the maximum tolerable dose. Reduced activity of DPD, resulting in reduced clearance and increased half-life of 5-uorouracil, results in increased risk of dose-dependent severe toxicities. [33] [34] [35] Morel et al. 18 compared the 5-uorouracil clearances of patients with DPYD*2A (n = 8 heterozygotes; n = 1 homozygote), *13 (n = 1 heterozygote), and rs67376798 (n = 10 heterozygotes) with those of patients without a 35 compared the 5-uorouracil clearances in patients with DPYD*2A (n = 2 heterozygotes) and rs67376798 (n = 7 heterozygotes) with the clearances in those with no relevant variant (n = 163). 5-Fluorouracil clearances in patients heterozygous for either DPYD*2A or rs67376798 were 80 and 40-58% (depending on treatment regimen), respectively, less than the clearances in the group with no variant. One patient had three heterozygote variants: DPYD*2A, rs67376798, and 85 T > C, resulting in a 5-uorouracil plasma clearance close to zero. Both studies found a signi cant di erence in grade 3-4 toxicities in patients with these variants as compared with patients lacking variants. ese data indicate that patients heterozygous for these variants have signi cantly reduced 5-uorouracil clearances, ranging from 40 to 80% less than the clearances in patients without these variants. Table 2 summarizes the genetics-based dosing recommendations for DPYD genotype and uoropyrimidines. e strength of the dosing recommendations is based on the facts that some variants (DPYD*2A, *13, and rs67376798) clearly a ect DPD activity, DPD activity is clearly related to 5-uorouracil clearance, and 5-uorouracil exposure is associated with its toxic e ects. erefore, reduction of uoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent uoropyrimidine-related toxicities. Supplementary Table S6 online summarizes the e ects of these variants on 5-uorouracil clearance and DPD activity. Although the data suggest that patients with the DPYD*2A variant may need a greater dose reduction than a patient with the rs67376798 variant, it is unclear to what extent the dose should be reduced. Furthermore, patients who are heterozygous for the nonfunctional DPYD variants mostly demonstrate partial DPD de ciency (leukocyte DPD activity at 30-70% that of the normal population). 16, 21, 26, 34, 35 us, our recommendation is to start with at least a 50% reduction of the starting dose; followed by an increase in dose in patients experiencing no or clinically tolerable toxicity, to maintain e cacy; and a decrease in dose in patients who do not tolerate the starting dose, to minimize toxicities. An alternative is pharmacokinetic-guided dose adjustment (if available). Patients who are homozygous for DPYD*2A, *13, or rs67376798 may demonstrate complete DPD de ciency, 17, 21, 23 and the use of 5-uorouracil or capecitabine is not recommended in these patients. Because capecitabine and tegafur are converted to 5-uorouracil and then metabolized by DPD, the clearance of and exposure to 5-uorouracil, in addition to its toxic e ects, are similar in patients with these variants. 23, 36 e US Food and Drug Administration (FDA) has added statements to the drug labels for 5-uorouracil (topical only) and capecitabine that contraindicate use in patients with DPD enzyme de ciency. e FDA drug label also warns to use precaution with intravenous 5-uorouracil in these patients. e Dutch Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for 5-uorouracil, capecitabine, and tegafur (5-uorouracil prodrug combined with uracil; not available in United States). 15 e Working Group recommends the use of an alternative drug for homozygous carriers of a decreased-activity allele and a reduced dose or alternative drug to capecitabine or 5-uorouracil for heterozygous carriers of a decreased-activity allele. 15 At the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or rs67376798 in 5-uorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that variant DPYD alleles would a ect 5-uorouracil metabolism di erently in children as compared with adults.
Dosage recommendations

Recommendations for incidental findings
DPD de ciency is a clinically heterogeneous autosomal recessive disorder of pyrimidine metabolism resulting in wide variability of clinical presentations. 28 ese symptoms generally present in childhood, with the majority of patients showing symptoms within the rst year of life. Currently, there is no correlation between symptom severity and DPD function and/or genetics. However, early diagnosis is crucial because of the potential of life-threatening defects. erefore, early phenotypic (e.g., urine screening of uracil and its degradation products) and/or genetic testing (pre-or postnatal) of o spring of DPYD-variant carriers could aid in early diagnosis and prevent unnecessary and costly diagnostic testing. 29, 37 Other considerations Some studies have suggested that the patient's gender may in uence the likelihood of 5-uorouracil toxicity, although the results have been contradictory and the mechanism is unknown. Several studies showed increased numbers of women, as compared with men, among patients with 5-uorouracil toxicity, 11, 26 although in one study, this was not signi cant when excluding patients with breast cancer, suggesting in that instance that the e ect may have been an artifact of di erent treatment regimens. 26 Early studies showed lower DPD activity and lower clearance of 5-uorouracil in women as compared with men. 38, 39 In one of the largest studies of DPYD variants and 5-uorouracil toxicity, the association of DPYD*2A with increased risk for toxicity was more signi cant in men than in women, even though there was no di erence between DPD activity and protein content in histologically normal liver tissues of male and female donors. 11 e use of folinic acid and the mode of 5-uorouracil infusion have also been associated with 5-uorouracil toxicity and should be considered when estimating a patient's individual risk of toxicity with 5-uorouracil (see ref. 11 for further information).
ere is some evidence from the work of Gamelin et al. 40 that individual pharmacokinetically guided dosing of 5-uorouracil therapy in patients with metastatic colorectal cancer improves treatment outcome with a reduced number of 5-uorouracil-related adverse drug reactions. Of note, in a recent paper by Deenen et al., data are provided indicating that the cumulative dose of capecitabine per course was signi cantly decreased in patients heterozygous for DPYD*2A (~50%) or rs67376798 (~25%) as compared with that in patients with the wild-type allele, and therapy could be continued safely in variant cases. Unfortunately, no data on capecitabine pharmacokinetics are included. Indirect determination of the endogenous uracil/dihydrouracil plasma ratio as a surrogate for DPD activity could be used to titrate 5-uorouracil-based chemotherapy with reduction of severe 5-uorouracil-related toxicities. 31
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
e main bene t to the patient would be the potential to avoid toxicity by using either alternative therapy or lower uoropyrimidine doses. e aim is to prevent the most severe and fatal instances of toxicity, but some patients who would not have experienced this degree of toxicity and who would have bene ted from uoropyrimidine therapy may be advised against it. Moreover, heterozygous patients who receive a lower dose of a uoropyrimidine and who would not have experienced this degree of toxicity may not experience the full bene t of uoropyrimidine therapy; therefore, it is important to increase the dose in patients experiencing no or clinically tolerable toxicity to maintain e cacy. Patients who proceed with 5-uorouracil therapy may still experience lower-grade toxicity that may be acceptable and even necessary in order to achieve e cacy. Some patients without a variant DPYD allele may still experience severe toxicity due to other genetic, environmental, or other factors.
A possible risk is the misreporting or misinterpretation of genotype test results. is mistake could be recorded in the patient record and could also in uence further treatments.
CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS
e positive predictive value and negative predictive value of DPYD*2A genotyping to predict development of severe toxicity (grade 3) are ~50 and ~95%, respectively; 11 however, taking into account other variant alleles, such as rs67376798 and DPYD*13, increases the positive predictive value to 62% (the negative predictive value remains unchanged). 18 Furthermore, the sensitivity calculated in this study for this genotype test was only 31%; therefore, the absence of these variants does not rule out DPD defects. Although many additional variants of DPYD are known (see Supplementary Tables S1, S3 , and S4 online), the frequencies are o en very low, and evidence for their functionality is limited.
DISCLAIMER
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines re ect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases that are not speci cally identi ed. Guidelines do not account for individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of CPIC's guidelines or for any errors or omissions.
